A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Sponsored by 858 Therapeutics, Inc.
About this study
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Enrolling at this location
University of Chicago Medical Center
Chicago, Illinois
I'm interestedThis study also enrolls at 13 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.